A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).

Trial Details

NCT ID

NCT06954246

Phase

PHASE3

Sponsor

Qilu Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

MHB088C for Injection
Topotecan
Irinotecan
Paclitaxel

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Participants must meet all the following criteria to be eligible for randomization into the study:
Voluntarily consent to participate in this study and sign the informed consent form.
Adults ≥18 years, regardless of gender.
ECOG performance status score of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →